Compugen sees "encouraging signals" from early-stage cancer trial [Yahoo! Finance News]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance News
TEL AVIV, April 27 ) - Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.COM701 was well-tolerated with no dose-limiting toxicities when administered alone and in combination with Bristol-Myers Squibb's cancer drug Opdivo nivolumab), Compugen said.Furthermore, COM701 demonstrated "encouraging signals of anti-tumour activity" with high disease control rate both as a monotherapy and in combination with Opdivo -- 69% and 75%, respectively, it said."I am highly encouraged by the safety profile and preliminary anti-tumour activity observed with COM701 both as a monotherapy and in combination with nivolumab," said Ryan Sullivan, assistant professor of medicine at Harvard Medical School and presenting author of the data at the virtual annual meeting of the American Association for Cancer Research.The Phase 1 clinica
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)Business Wire
- Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.MarketBeat
- How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.MarketBeat
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website